AD 20: designed to reduce toxicity or enhance activity of anticancer drugs [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 159468 |
MeSH ID | M0150953 |
Synonym |
---|
ccris 3396 |
111542-07-5 |
2-[[2-(2-methoxyphenyl)acetyl]amino]prop-2-enoic acid |
ad 20 |
ad20 |
o-methoxyphenylacetyl dehydroalanine |
2-propenoic acid, 2-(((2-methoxyphenyl)acetyl)amino)- |
ad-20 |
tje9ae2975 , |
unii-tje9ae2975 |
n-(2-methoxyphenylacetyl)dehydroalanine |
2-propenoic acid,2-[[2-(2-methoxyphenyl)acetyl]amino]- |
DTXSID40149689 |
2-((2-(2-methoxyphenyl)acetyl)amino)-2-propenoic acid |
2-propenoic acid, 2-((2-(2-methoxyphenyl)acetyl)amino)- |
(o-methoxyphenylacetyl)dehydroalanine |
AKOS040745478 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (62.50) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (53.90) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |